08:50 AM EDT, 10/11/2024 (MT Newswires) -- Acrivon Therapeutics ( ACRV ) said Friday that the first patient has been dosed in its phase 1 clinical trial evaluating ACR-2316, which is being developed to treat patients with solid tumors.

The company said the trial will determine the maximal tolerated dose and recommended phase 2 monotherapy dose, characterization of the pharmacokinetic profile and preliminary evaluation of anti-tumor activity.

Price: 7.00, Change: +0.02, Percent Change: +0.29